Biotech Strategy

Glue sounds almost too gentle for Alzheimer’s disease. The usual business pitch for AI drug discovery prefers a louder vocabulary: acceleration, disruption, de-risking, platform advantage, and occasionally “revolution,” because apparently no investor memo can survive without one. This paper is more interesting when read against that noise. It does not show that AI has found an Alzheimer’s drug. It does not show that amyloid-β42 has been degraded in cells. It does not show brain delivery, toxicity control, animal efficacy, or clinical relevance. ...

TL;DR for operators A recent paper proposes programmable virtual humans (PVHs): dynamic, multiscale computational models intended to simulate how a new molecule moves through, interacts with, and perturbs human biology from molecular binding to clinical phenotype.1 The operational point is not that pharma now has a magic patient simulator. It does not. The paper is a perspective and roadmap, not a benchmarked product release with clinical validation, regulatory acceptance, and a procurement form attached. Shame, really. ...